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The use of radiolabelled antibodies and antibody-derived recombinant constructs have shown 
promise for both imaging and therapeutic use. In this context, the biotin-avidin/streptavidin pairing 
along with the inverse electron demand Diels–Alder reaction (IEDDA) have found application in pre-
targeting approaches for positron emission tomography (PET). This study reports the fluorinase 
enzyme mediated transhalogenation (ClDA substrates to FDA products) of two antibody pre-targeting 
tools, a FDA-PEG-tetrazine and a [18F]FDA-PEG-biotin and each is assessed for their compatibility 
towards IEDDA ligation to trans-cyclooctene or affinity to avidin. A protocol was developed to avoid 
radiolytically promoted oxidation of biotin during the synthesis of [18F]FDA-PEG-biotin. The study adds 
to the repertoire of conjugates for use in fluorinase catalysed radio-synthesis for PET and shows that 
the fluorinase will accept a wide range of ClDA substrates tethered at C-2 of the adenine ring with a 
pegylated cargo. The method is exceptional as the nucleophilic reaction with [18F]fluoride takes place 
in water at neutral pH and at ambient temperature. 
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Introduction 
Positron emission tomography (PET) has emerged as a valuable tool in clinical imaging due to its high 
sensitivity and complementarity to other in vivo clinical imaging modalities, such as computerised 
tomography (CT) and magnetic resonance imaging (MRI).[1] [18F]Fluoride is the most commonly used 
radionuclide for PET imaging as it possesses a relatively long half-life (t1/2 = 109.8 min) for a clinical 
positron emitter and image resolution is enhanced as it has a short positron range (2.3 mm in water). 
A recent drive to improve imaging performance by PET has led to a shift from the direct labelling of 
traditional low molecular-weight and rapidly circulating (hours) radiotracers, which often suffer non-
specific binding and poor localisation in vivo, to the use of large but very high affinity proteins such as 
monoclonal antibodies or their fragments, which circulate much more slowly (days).[2] Such proteins 
cannot be usefully labelled by fluorine-18 at point of injection as the isotope half-life is inconsistent 
with the pre-incubation time required for their location at the target. Instead, a pre-targeted approach 
is required where the antibody is administered in its unlabelled form, but with a reactive motif 
attached, and then several hours to days later, a low molecular weight 18F-labelled reactive partner is 
administered which circulates rapidly and covalently modifies the in situ antibody. Such strategies 
have begun to exploit bioorthogonal click reactions[3] and make use, for example, of strain promoted 
alkyne–azide cycloaddition (SPAAC) or inverse electron demand Diels–Alder reactions (IEDDAs), 
without the need for catalysis.[4] IEDDA based methods in particular involve complimentary tetrazine 
and trans-cyclooctene (TCO) motifs which combine remarkably rapidly (reaction rates up to k2 2000 
M-1 s-1 in 9:1 methanol/water),[4d] allowing for protein modification at low radiotracer concentrations. 
 
 
 
 
 
 
 
 
 
 
Scheme 1.  Schematic diagrams of pre-targeting approaches to PET. A)  The inverse electron demand Diels–Alder 
(IEDDA) bioorthogonal click reaction. B) The (+)-biotin/(strep)avidin affinity pairing. 
In this context, the intitial approach has been to fluorinate the TCO motif as direct nucleophilic 
fluorination of the reactive tetrazine motif is challenging due to decomposition.[5] Thus efficient 
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methods for radiolabelling tetrazines with fluorine-18 are desirable.[6] In this regard an Al[18F]NOTA-
labelled tetrazine tracer was successfully utilised in a pre-targeting PET study, expressing BxPC3 
pancreatic cancer xenografts in mice.[4c] There remains room to explore other 18F-labelled tetrazine 
strategies and in this study we have investigated enzymatic fluorination in water/buffer under 
ambient conditions. 
Similarly, pre-targeting strategies have been designed around the (+)-biotin/(strep)avidin affinity 
pairing.[7] The interaction is among the strongest non-covalent interactions (Kd = 1 x 10-15 M) known 
and is unaffected by extremes of pH and temperature. Initial approaches to multistep imaging 
involved the use of unlabelled antibodies conjugated to (+)-biotin, followed by the administration of 
radiolabelled (strept)avidin.[8] Alternatively, a more efficient pre-targeting approach involves the 
administration of large (strept)avidin-antibody conjugates, followed by a rapidly circulating, low 
molecular weight [18F]biotin derivative.[9] There has been concern when employing this strategy 
regarding the role of endogenous biotin competing with the radiolabelled chaser in vivo, though this 
has been successfully addressed in mice models through a biotin-deficient diet.[10] 
Radiolabelling of (+)-biotin has generally been achieved through the pre-synthesis and then coupling 
of 18F-labelled prosthetic groups, typically [18F]4-fluorobenzylamine[7b], p-[18F]fluorobenzoic acid[10b] 
and [18F]FDG[11]. The approach involves several steps and requires efficient fluorination strategies. 
Direct labelling approaches, such as the nucleophilic fluorination of a (+)-biotin-mesylate precursor 
are more appealing.[12] We have been exploring an even more direct approach involving enzymatic 
fluorination, which can be accomplished without drying the [18F]fluoride which is generated in a 
cyclotron in [18O]water, prior to nucleophilic chemistry. Such an approach requires minimal 
manipulation of the radioisotope. A similarly direct approach has been explored with boroaryl 
functionalized (+)-biotin,[13] however in order to avoid deboronylation during the radiolabelling 
protocol, a low pH is required. 
10.1002/cbic.201800234
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemBioChem
This article is protected by copyright. All rights reserved.
 Scheme 2. A) The native reaction catalyzed by the fluorinase enzyme. B) Fluorinase mediated transhalogenation 
reaction of C-2 modified substrates, 6 and 7 exemplify previously achieved alkyne/azide "click"[14] and barbas 
linker/thiol-ligation[15] bioconjugation strategies. 
The fluorinase enzyme catalyses the conversion of S-adenosyl-L-methionine (AdoMet) and fluoride 
ion to generate 5'-fluoro-5'-deoxyadenosine (5'-FDA, Scheme 2).[16] It also catalyses the nucleophilic 
displacement of chloride by L-methonine in the reverse direction to generate AdoMet,[17] and if 
fluoride is present in this reaction 5'-FDA is formed in a sequential step, such that an overall 
transhalogenation reaction occurs. Moreover, the replacement of AdoMet with AdoSeMet increases 
the overall transhalogenation efficiency, as selenium is a better nucleophile and leaving group than 
sulfur (Scheme 2). The fluorinase displays a high degree of substrate specificity, however it can 
tolerate an acetylene moiety at the C2 position on the adenine base of 5'-ClDA, additionally a 
pegylated cargo can also be tethered to the terminus of this acetylene. In this way the fluorinase will 
catalyse ‘last-step’ aqueous [18F]fluorination of 5'-ClDA-PEG-peptides.[14] To date, methodologies to 
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permit bioconjugation of RGD peptides to the fluorinase binding 5'-ClDA moiety either through ‘click’ 
based chemistry (via azide functionalized peptides)[14, 18] or utilising a modified Barbas bioconjugation 
strategy (via cysteine containing peptides)[15] have been developed (Scheme 2). Recently, the 
fluorinase enzyme has also become the target of engineering via directed evolution, in an effort to 
achieve higher radiochemical conversions (RCC) and broaden the structural diversity of substrates.[19] 
 
Scheme 3. Design of fluorinase binding ClDA-PEG-acid 8 and ClDA-PEG-amine 9 constructs for amide bond 
ligation to biologically relevant molecules. 
In order to demonstrate a wider array of conjugation methods (employing amide linkage via ClDA-
PEG-acid 8 and ClDA-PEG-amine 9, Scheme 3) compatible with fluorinase labelling of higher molecular-
weight proteins, we now report the fluorinase mediated transhalogenation of  ClDA-PEG-tetrazine 16 
to FDA-PEG-tetrazine 17 demonstrating compatibility with the tetrazine ring under ambient, aqueous 
conditions. Similarly ClDA-PEG-biotin 26 was used in a proof of principle study to deliver a biotin 
radiotracer, [18F]27, as a tool for radiolabelling pre-targeted (strept)avidin conjugated antibodies. 
 
Results and Discussion 
Synthesis of ClDA-PEG-acid 8 and ClDA-PEG-tetrazine 16 
A three step approach was employed for the synthesis of both ClDA-PEG-tetrazine 16 and ClDA-PEG-
biotin 26.[14, 18b] This involved the synthesis of a fluorinase compatible 5'-chloro-5'-deoxyadenosine 
attached to an amine (9) or carboxylic acid (8) functionality through a PEG spacer. Amide coupling to 
either benzylamino tetrazine 15 or the carboxylate of (+)-biotin 25, generated tetrazine 16 (Scheme 
4) or ClDA-PEG-biotin 26 (Scheme 5) constructs respectively. Briefly, 5'-chlorodeoxy-2-iodo-adenosine 
13, a key intermediate in these syntheses, was prepared from guanosine using a previously established 
protocol.[18b] The synthesis of 16 required that the pegylated linker was functionalized with an alkyne 
terminus. This was accomplished by first treating tetraethylene glycol 10 with propargyl bromide to 
provide the monoalkylated PEG derivative 11, which, after purification, was treated with tert-butyl 
bromoacetate to afford 12. This PEG linker serves two purposes; firstly, it aids in the aqueous solubility 
of the conjugate, an essential requirement for fluorinase catalysis. Secondly, the linker serves to 
project any functionalized moiety from the surface of the fluorinase and into the bulk solvent.   
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Scheme 4. Synthesis of ClDA-PEG-acid 8, ClDA-PEG-tetrazine 16 and FDA-PEG-tetrazine 17. Reagents and 
conditions: a) NaH, propargyl bromide, THF,  0 °C to r.t., overnight; b) NaH, tert-butyl bromoacetate, THF,  0 °C 
to r.t., overnight; c) Pd2(dba)3, Et3N, CuI, DMF, 80 °C, 24 h; d) TFA, DCM, 0 °C to r.t., 45 min; e) PyBOP, DIPEA, 
DMF, r.t., 24 h; f) Fluorinase, L-Se-Met, KF, phosphate buffer (pH 7.8), 37 °C, 72 h. 
With both 12 and 13 in hand, our attention turned to further assembly via Sonogashira cross-coupling. 
This was accomplished,[20] using an excess of alkyne 12 over 5'-chlorodeoxy-2-iodo-adenosine 13 in 
the Pd2(dba)3 catalysed reaction. The ClDA-PEG-ester 14 was recovered in high purity after 
chromatography and C18 cartridge purification. ClDA-PEG-ester 14 was treated with TFA to generate 
8 as a TFA salt, and this could be used directly in the subsequent coupling reactions, without the need 
for further purification. Finally, an amide coupling reaction (PyBOP, DIPEA) was employed to attach 
carboxylic acid 8 to benzylamino tetrazine 15 (Scheme 4). This afforded the ClDA-PEG-tetrazine 16 
conjugate in high purity after preparative HPLC. 
 
Evaluation of ClDA-PEG-tetrazine as a substrate for fluorinase mediated transhalogenation 
Substrate 16 was incubated with the fluorinase (1 mg mL-1, these relatively high amounts are due to 
the fluorinase having a slow kcat of 0.03 min−1)[17] under previously established conditions in 
phosphate buffer at pH 7.8 (see Supporting Information). A time course profile (Figure 1) showed that 
16 was an excellent substrate for enzyme catalysed transhalogenation generating FDA-PEG-tetrazine 
17, in ~60% conversion after 4 h, and this offers a new approach to fluorinating tetrazine derivatives. 
Importantly, no obvious degradation was observed within the initial hours of these experiments (the 
timeframe required for radiolabeling experiments), indicating that ClDA-PEG-tetrazine and its 
fluorinated analogue are stable under these conditions. The additional peak observed at 12.5 min is 
indicative of the intermediate L-Se-Met adduct (which consistently possesses a greater retention time 
to that of its corresponding ClDA and FDA derivatives). 
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Figure 1. HPLC time course (UV, 254 nm) of the incubation of ClDA-PEG-tetrazine 16, blue (tR = 11.9 min), with 
the fluorinase, L-Se-Met, KF, phosphate buffer (pH 7.8) at 37 °C. Traces show the formation of FDA-PEG-tetrazine 
17, purple (tR = 10.8 min), and the consumption of ClDA-PEG-tetrazine 16. For full conditions see the 
Experimental Section and Supporting Information. 
 
ClDA-PEG-tetrazine/dienophile IEDDA ligation  
With FDA-PEG-tetrazine 17 in hand, it was explored for its ability to participate in IEDDA-initiated 
ligation. For this study (E)-cyclooct-4-enol 18 was chosen as a coupling partner. Thus, a solution (40 
μl, 50 mM) of (E)-cyclooct-4-enol in DMSO was added to an aqueous solution of 17, and the mixture 
was incubated at room temperature for 2 min. An aliquot was then subjected to HPLC and HRMS 
analysis of the new product isolated was consistent with the formation of the fully aromatised ligated 
product 19 (Scheme 5). 
 
 
 
 
Scheme 5. IEDDA initiated conjugation between 17 and (E)-cyclooct-4-enol 18 (identity of fully aromatised 
ligation product 19 was confirmed by HRMS after isolation by HPLC.  
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Last step enzymatic 18F labelling of 16 to [18F]FDA-PEG-tetrazine 
An enzymatic transhalogenation in the presence of [18F]fluoride was investigated with 16 and its 
conversion into [18F]FDA-PEG-tetrazine ([18F]17) was clearly demonstrated against a product 
reference. Using the previously established protocol,[15] [18F]17 was generated with an approximate 
10% radiochemical conversion (decay uncorrected) after a 30 min incubation with the fluorinase 
(Figure S46). Isolation of [18F]17 by semi-prep HPLC afforded the radiolabelled product with two minor 
radiolabelled impurities (Figure S47). This process requires optimisation for pre-clinical dosing, 
however it is clear that the tetrazine moiety is compatible with the fluorinase radiolabelling protocol. 
 
Synthesis of ClDA-PEG-amine 9 and ClDA-PEG-biotin 26 
The synthesis of ClDA-PEG-biotin 26 followed a similar strategy to that used for ClDA-PEG-tetrazine 
16. Firstly, a pegylated linker was required with alkyne and amine termini. For this alcohol 11 was 
treated with tosyl chloride and then 20 was subjected to nucleophilic displacement with sodium azide 
to generate azide 21. A Staudinger reduction of this azide afforded free amine 22, which was then Boc 
protected to generate 23.  
 
Scheme 6. Synthesis of ClDA-PEG-amine 9, ClDA-PEG-biotin 26 and FDA-PEG-biotin 27. Reagents and conditions: 
a) NaH, propargyl bromide, THF,  0 °C to r.t., overnight; b) Tosyl chloride, Et3N, THF, r.t., 20 h; c) NaN3, DMF, 50 
°C, 18 h; d) PPh3, H2O, THF, r.t., 48 h; e) (Boc)2O, Et3N, MeOH; f) Pd2(dba)3, Et3N, CuI, DMF, 80 °C, 24 h; g) TFA, 
DCM, 0 °C to r.t., 45 min; h) PyBOP, DIPEA, DMF, r.t., 24h; i) Fluorinase, L-Se-Met, KF, phosphate buffer (pH 7.8), 
37 °C, 48 h. 
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A Sonogashira cross-coupling was carried out with an excess of alkyne 23 over 5'-chlorodeoxy-2-iodo-
adenosine 13 using the previously described protocol to generate ClDA-PEG-protected amine 24, after 
HPLC purification, in high purity. Deprotection of 24 with TFA led to free amine 9 (as a TFA salt) which 
was used directly in subsequent coupling reactions, without the need for further purification. As with 
carboxylic acid 8, amine 9 offers a complementary tool for the fluorinase [18F]-labelling, for 
conjugation to the C-termini of bioactive peptides. Amide coupling (PyBOP, DIPEA) allowed 
preparation of the ClDA-PEG-biotin conjugate 26 in good yield and high purity after HPLC purification.  
 
Evaluation of ClDA-PEG-biotin as a substrate for fluorinase mediated transhalogenation 
As a prelude to [18F]-radiolabelling a ‘cold’ transhalogenation reaction with ClDA-PEG-biotin 26 was 
explored with the fluorinase. Accordingly, substrate 26 was incubated with the fluorinase (1 mg mL-1) 
L-Se-Met (75 μM) and KF (50 mM) in phosphate buffer, at pH 7.8 (see Supporting Information). An 
analytical time course profile revealed chloride 26 to be an excellent substrate for fluorinase mediated 
transhalogenation generating FDA-PEG-biotin 27, with an almost 80% conversion after 4 h. No 
reaction was observed in the absence of the fluorinase and the water solubility of 26 circumvented 
any requirement to add DMSO. A significant advantage in such reactions, as adding DMSO can 
complicate work up by promoting gelling on heat denaturation. 
Figure 2. HPLC time course (UV, 254 nm) of the incubation of ClDA-PEG-biotin 26, green (tR = 9.5 min), with the 
fluorinase, L-Se-Met, KF, phosphate buffer (pH 7.8) at 37 °C. Traces show the formation of FDA-PEG-biotin 27, 
yellow (tR = 8.9 min), and the consumption of ClDA-PEG-biotin 26. For full conditions see the Experimental 
Section and Supporting Information. 
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 The transhalogenation of 26 was carried out on a scale sufficient for isolation of an analytical sample 
of FDA-PEG-biotin 27 to confirm its identity by NMR. A suitable sample was also required to evaluate 
its binding affinity to avidin (see Supporting Information). The reaction was again monitored by HPLC 
and was terminated by heat precipitation and centrifugation to remove the enzyme. Purification was 
accomplished via semi-prep HPLC to obtain 27 (3mg) in high purity. 
 
 
FDA-PEG-biotin/avidin Binding Assay 
The avidin binding affinity of the newly synthesised FDA-PEG-biotin 27 was determined using a 
colorimetric HABA assay. The assay exploits the UV spectral changes that occur upon the binding of 
4'-hydroxyazobenzene-2-carboxylic acid (HABA) to avidin. The HABA/avidin interaction is a relatively 
weak one (Kd = 5.8 x 10-6 M versus that of (+)-biotin/Avidin; Kd = 1 x 10-15 M), and as such free (+)-biotin, 
or indeed 27, will readily displace the HABA dye and result in a decrease in absorbance at 500nm 
wavelength. FDA-PEG-biotin 27 was found to inhibit the HABA/avidin complex in a dose dependant 
manner (Figure 3) and with a similar affinity to that between avidin and (+)-biotin. The PEG spacer and 
the FDA moiety of the construct do not impede the binding interaction of 27 with avidin, thus [18F]27 
has good potential as a candidate tracer for streptavidin-conjugated antibody PET studies.  
 
 
 
 
 
 
 
 
 
 
Figure 3. Inhibition of the HABA/avidin complex by (+)-biotin (maroon squares) and FDA-PEG-biotin 27 (blue 
circles). Data are representative of three different experiments. 
 
Last step enzymatic 18F labelling of biotin 
An enzymatic transhalogenation was performed with 26 in the presence of [18F]fluoride, and its 
conversion into [18F]FDA-PEG-biotin ([18F]27) was monitored. For hot labelling an [18O]aqueous, 
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solution of [18F]fluoride at GBq levels is generated and then an aliquot (MBq of [18F]fluoride) is added 
to the biotransformation solution in buffer at pH 7.8 (see Experimental Section). The concentrations 
are such that these fluorinase-catalyzed radiochemical reactions are no longer catalytic, as the enzyme 
is in the micromolar range with [18F]fluoride ion in the pico-molar range. In this manner the 
stoichiometry is dramatically reversed relative to the cold transhalogenation reactions. During these 
experiments [18F]27 was produced with a 30-40% radiochemical conversion after only 30 min 
incubation with the fluorinase. Figure 4 shows the radiochemical HPLC trace of the supernatant of a 
reaction mixture at this time point.  
 
 
Figure 4. (A) Reaction scheme of the fluorinase catalysed transhalogenation of 26 to [18F]FDA-PEG-biotin 
([18F]27). (B) HPLC radioactivity trace of a fluorinase catalysed conversion of ClDA-PEG-biotin 26 to [18F]27 in the 
presence of 18F-, L-Se-Met in phosphate buffer (pH 7.8), at 37 °C after 30 min incubation. [18F]27 was observed 
at tR = 9.7 min, showing 40% radiochemical conversion during this experiment.  
After a 30 min incubation,[15] the enzyme was cleanly precipitated by heat denaturation and the 
solution removed after centrifugation, prior to purification by HPLC. During semi-prep HPLC the eluted 
peak corresponding to [18F]27 was collected (Figure 4, tR = 9.7 min), diluted with water (50 mL) and 
loaded onto a C18 reverse phase cartridge, which was then washed with water (20 mL) and [18F]27 
eluted with ethanol. The purity of [18F]27 was determined by analytical radio-HPLC. This revealed the 
existence of an additional radioactive peak at tR = 4.3 min (Figure 5). A typical procedure from 
[18F]fluoride (457 MBq) to the elution of [18F]26 (59.7 MBq) took 1 h 19 min. After semi-prep HPLC and 
C18 cartridge purification, [18F]27 was recovered with a radiochemical yield of 13% (decay 
uncorrected) and a radiochemical purity of 90%. 
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 Figure 5. Analytical HPLC radio trace of [18F]FDA-PEG-biotin ([18F]27) acquired using standard purification 
protocols (red) and optimized purification protocols (black). Structures of [18F]FDA-PEG-biotin ([18F]27, tR = 5.7 
min) and [18F]FDA-PEG-biotin sulfoxide ([18F]28, tR = 4.3 min) are shown. For full conditions see the Experimental 
Section and Supporting Information. 
 
Optimisation of [18F]FDA-PEG-biotin purification protocol  
The chemical identity of the impurity (10%, tR = 4.3 min, Figure 5) in the analytical radio-HPLC trace 
was elucidated by mass spectrometry analysis. An equivalent peak could be observed in 
nonradioactive storage of a solution of 26 in MeCN/H2O at room temperature where the conversion 
to product 28 is slow (3% at 48 h). Isolation by semi-prep HPLC and analysis by LC-MS found a [M+H]+ 
mass of 741 amu, consistent with FDA-PEG-biotin sulfoxide (28) (see Figure 5). Indeed, previous 
studies concerning the radiolabelling of biotin observed a similar outcome.[21] Furthermore, biotin 
sulfoxide is a known product in mammalian catabolism, and is observed in both urine and plasma.[22] 
The sulfoxide is also known to bind avidin,[23] and thus ([18F]28) low levels are unlikely to negatively 
affect PET studies, however we sought to exclude it from the biotransformation. Studies focused on 
the radiolytic decomposition of concentrated radiopharmaceuticals[24] indicate that reactive oxygen 
species (hydroxyl radicals and/or hydrogen peroxide) can be detrimental, and such species could 
clearly account for the sulfur oxidation of [18F]28. In an effort to minimize the formation of [18F]28, the 
fluorinase mediated radiolabelling was repeated however in this instance making use of degassed 
eluting solvents and established anti-oxidant stabilisers. Approximately the same levels of 
radioactivity (~70 MBq) was collected by semi-prep HPLC into a vial containing 10 mg/mL ascorbate (a 
known radical scavenger which is amenable to human use) in water solution (45 mL, degassed). This 
solution was loaded directly onto the C18 cartridge which had been pre-equilibrated with the same 
degassed solution and [18F]27 was then eluted with ethanol (0.4 mL). HPLC analysis of the [18F]27 
revealed it to be free of [18F]28, and with a radiochemical purity of >99% (see Figure 5). Furthermore, 
the stability of [18F]27 in the ethanol fraction (left open to the atmosphere) was monitored over time 
by using formulations of both water and aqueous ascorbate (10 mg/mL) solution. This did not reveal 
any appreciable oxidation of [18F]27. Under these optimised conditions there was no observable 
degradation of either [18F]27 or its chlorinated precursor. Such stability affords the prospect of the 
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development of an automated recycling protocol, potentially incorporating immobilised enzyme (to 
circumvent the need for centrifugation), to be used in the synthesis of [18F]27 to allow for the 
formulation of higher doses. This fluorinase mediated 18F-labelling methodology provides a novel 
route into [18F]biotin in the form of [18F]27, and demonstrates a direct ‘last step’ labelling approach 
through the formation of a chemically stable C-18F bond from a chlorinated precursor. Furthermore, 
after optimization of the purification protocol with the use of non-toxic radical scavengers, a 
radiochemically pure sample of [18F]27 was achieved.   
   
 [18F]FDA-PEG-biotin streptavidin binding experiments 
To confirm the utility of [18F]27 as a candidate PET tracer for clinical use an assessment of its the 
streptavidin binding affinity was performed. Accordingly [18F]27 was incubated in PBS buffer (pH 7.8) 
in the presence and absence of streptavidin (see Supporting Information).  Thin layer chromatography 
was then conducted on both samples (+/- streptavidin) which were analysed using a radio-TLC scanner 
to determine the percentage of streptavidin bound [18F]27. The radio-traces obtained from samples 
[18F]27 incubated without streptavidin revealed a broad peak with a R/F value of 0.39. Upon 
incubation with streptavidin [18F]27 is almost completely retained (above 96%) at the origin of the TLC 
plate (R/F value of 0.02, see Supporting Information) indicating its almost complete complexation with 
streptavidin. This finding is in accordance with the high affinity binding of non radioactive FDA-PEG-
Biotin 27 and avidin. 
 
Conclusions 
A FDA-PEG-tetrazine construct 17 and a radiolabelled labelled (+)-biotin derivative [18F]27 were 
generated from their ClDA-chlorinated precursors 16 and 26 respectively. In both cases each was 
shown to efficiently couple to models of their complementary partners anticipated for in vivo studies. 
As part of the study a protocol to avoid radiolytically triggered oxidation of [18F]27 was developed. 
This adds to the repertoire of conjugates for use in fluorinase catalysed radio-synthesis for PET and 
shows that the fluorinase will accept a wide range of ClDA substrates tethered at C-2 of the adenine 
ring with a pegylated cargo. 
 
Experimental Section 
Cold Transhalogenation assay  
A typical cold transhalogenation assay is exampled in 26. In a total reaction volume of 1000 μL (in 50 
mM phosphate buffer, at pH 7.8), recombinant fluorinase (0.8 mg/mL−1) was incubated with ClDA-
PEG-biotin 26 (0.1 mM), L-Se-Met (0.075 mM) and KF (50 mM) at 37 °C. Samples (50 μL) were 
periodically removed, the protein precipitated by heating at 95 °C for 5 min, before being clarified by 
centrifugation (13 000 rpm, 10 min). Samples of the supernatant (40 μL) were removed for analysis by 
HPLC. HPLC analysis was performed on a Shimadzu Prominence system using a Kinetix 5 μm XB-C18 
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100A (150 mm × 4.6 mm) column and a guard cartridge. Mobile phase: 0.05% TFA in water (solvent A) 
and 0.05% TFA in MeCN (solvent B); Linear Gradient: 15% solvent B to 95% solvent B over 25 min, 95% 
for 5 min, and back to 15% B for 10 min to re-equilibrate the column. Flow rate: 1 mL/min−1; Detection: 
254 nm; Injection volume: 40 μL. 
 
HABA Assay 
Preliminary experiments were performed varying the concentrations of HABA and avidin to determine 
the optimal conditions for the competitive binding studies. In the final experiments a range of 
concentrations (0-200 μM) of FDA-PEG-Biotin 27 and (+)-biotin were added to a HABA/avidin complex, 
obtained by mixing avidin and HABA to final concentrations of (2.5 mg/ml) and 0.25 μM respectively. 
Changes in absorbance were measure at 500 nm and the % inhibition was calculated using the 
following formula: {[(absorbance with competitor) − (absorbance without HABA)/(Av 
complex)]/[(absorbance without competitor) − (absorbance without HABA)/(Av complex)]} × 100. 
 
[18F] Labelling of 26 to [18F]27 
A typical 18F- labelling experiment of 26 was performed as follows: L-selenomethionine (40 μL of a 
2mM solution in water) and compound 26 (0.4 mg in 50 μL of water) were added successively to an 
Eppendorf tube containing a solution of fluorinase (5 mg in 50 mm phosphate buffer, 110 μL). The 
contents were mixed well with a pipette and to this mixture was added [18F-]fluoride in [18O]water 
(457 MBq, 50 μL), making a total volume of 250 μL. The contents were again well mixed and incubated 
at 37 °C for 30 min. After this time the reaction was stopped and the mixture denatured by heating at 
95 °C for 5 min and water (400 μL) added before being clarified by centrifugation (13 000 rpm, 
corresponding to 16060 g, 5 min). The supernatant was injected into a Shimadzu Prominence HPLC 
system equipped with a quaternary pump, a degasser, a flow cell detector and a diode array detector 
using a Phenomenex Kingsorb C18 (250 × 10.00 mm, 5 μm) column and a guard cartridge. Mobile 
phase: 0.05% TFA in water (solvent A) and 0.05% TFA in MeCN (solvent B); Linear Gradient: 15% 
solvent B to 38% solvent B over 16 min, 95% for 5 min, and back to 15% B for 10 min to re-equilibrate 
the column. Flow rate: 5 mL/min−1. The radioactive fraction corresponding to the reference of [18F]27 
was collected, diluted with 10 mg/mL ascorbate in water (50 mL) and loaded onto a preactivated 
Waters Oasis HLB® Cartridge (conditioned with 2 mL EtOH and 5 mL 10 mg/mL ascorbate/water). The 
cartridge was washed with 20 mL of 10 mg/mL ascorbate/water and the desired product was collected 
by eluting with 0.6 mL of ethanol, to give 59.7 MBq (13 %, decay uncorrected) of >99% pure product 
of [18F]27.  
 
Streptavidin binding Radio TLC assay 
To PBS buffer (300 μL, pH 7.8) or streptavidin (0.6 mg) in PBS buffer (300 μL, pH 7.8) was added [18F]27 
(0.8 MBq, in a 50 L solution of 1:5 EtOH:water), the reaction mixture was mixed well and incubated 
at 37 ◦C for 30 min. Thin layer chromatography was then conducted on both samples (+/- streptavidin) 
using aluminium plates coated with silica gel (60F245 Merck), eluted with a solution 75:25:5 
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MeCN:MeOH:Water. TLC plates were examined using a radio-TLC scanner to determine the 
percentage of streptavidin bound [18F]27. Thin layer chromatograms radio-traces of the samples 
[18F]27 in PBS buffer revealed an R/F value of 0.39, upon incubation with streptavidin thin layer 
chromatograms radio-traces indicated almost completely retention of [18F]27 (about 96%) in the origin 
of the TLC plate (R/F value of 0.02, see Supporting Information for full experimental details and 
Figures). 
 
See Supporting Information for experimental detail on: Compound synthesis and characterisation, 
assay conditions and fluorinase overexpression and purification. 
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